October 21, 2016 by riskreversal • Trade Ideas

Biotech stocks have been a disaster so far in 2016, with Nasdaq Biotech etf IBB down 20% ytd, and down 34% from its all time highs (in August 2015), and S&P Biotech etf XBI down …

Continue reading
July 7, 2016 by Dan • FREE ACCESS

Lat Friday on CNBC’s Options Action, we discussed the under-performance of Biotech stocks in the first half of 2016. Meg Tirrell highlighted the large cash balances of mega-cap biotechs, and the potential for a second half …

Continue reading
April 25, 2016 by Dan • Commentary

For week’s now my co-panelist on CNBC’s Options Action, Carter Worth of Cornerstone Macro Research has been making the bullish case for the Biotech stocks, specifically looking at the IBB, the iShares Nasdaq Biotech etf. …

Continue reading
November 12, 2015 by CC • Commentary

A little over a week ago we took a look at Bio/Pharmatech stocks and offered a way to fade the recent bounce in the sector in the very near term. It’s our belief that the scrutiny …

Continue reading
November 6, 2015 by Dan • Commentary

On Wednesday we laid out a bearish trade idea in the IBB, the iShares Nasdaq Biotech etf (read here) largely as a result of a poor technical set up, poor relative performance to other market …

Continue reading
November 4, 2015 by Dan • Commentary

I guess people think it’s safe to go back in the pool. The S&P 500 (SPX) is now up 2% on the year, and just 1% from the previous all time highs. Regular readers know that …

Continue reading